Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia

• Published in: Journal of clinical psychopharmacology Vol. 36; no. 6; p. 580
• Main Authors: González-Rodríguez, Alexandre, Catalán, Rosa, Penadés, Rafael, Ruiz Cortés, Victoria, Torra, Mercè, Seeman, Mary V, Bernardo, Miquel
• Format: Journal Article
• Language: English
• Published: United States 01.12.2016
• Subjects: Aged; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - pharmacology; Female; Humans; Middle Aged; Outcome Assessment (Health Care); Postmenopause; Prospective Studies; Schizophrenia - blood; Schizophrenia - drug therapy; Schizophrenia - physiopathology; Smoking; Time Factors
• ISSN: 1533-712X
• DOI: 10.1097/JCP.0000000000000571

The loss of estrogens in the menopause may lead to increased vulnerability for psychotic relapse, poor clinical outcome, and a need for increased antipsychotic dose. However, confounders such as cumulative estrogen exposure and time since menopause have been inadequately studied. Our aim was to investigate potential variables capable of influencing antipsychotic response in a sample of postmenopausal women with schizophrenia. Sixty-four postmenopausal schizophrenic women were followed in a 12-week prospective treatment-by-clinical requirement study. Duration of reproductive years was considered an indirect measure of lifetime cumulative estrogens exposure. Psychopathological assessment included the following: Positive and Negative Syndrome Scale, Personal and Social Performance, and Clinical Global Impression-Schizophrenia Scale. Response was defined as a reduction of 30% or more of Positive and Negative Syndrome Scale total scores. Antipsychotic adherence was assessed by plasma level monitoring at 4 weeks. Regression analyses were performed to investigate the association between potential confounding factors and antipsychotic response. Forty-two participants (66%) were found to be antipsychotic responders. Time since menopause was significantly and negatively associated with overall antipsychotic response, explaining almost 42% of the variance of the model used. Smoking and cumulative estrogen exposures were associated with improvement in negative symptoms. Smoking and time since menopause were associated with improvement in excitement symptoms, and smoking was positively associated with improvement in depressive and cognitive symptoms. Time since menopause was significantly negatively associated with antipsychotic response in postmenopausal schizophrenic women, suggesting a decline in antipsychotic response after menopause. The neurobiological basis for antipsychotic response may include a role for estrogen and nicotine receptors.